- Home
- CWST vs DNTH Comparison
CWST vs DNTH Comparison
Compare CWST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWST | DNTH |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.9B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CWST | DNTH |
|---|---|---|
| Price | $93.23 | $82.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $106.50 | ★ $139.06 |
| AVG Volume (30 Days) | 672.4K | ★ 864.5K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,836,841,000.00 | $2,036,000.00 |
| Revenue This Year | $14.49 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.95 | N/A |
| 52 Week Low | $74.05 | $32.28 |
| 52 Week High | $107.96 | $117.88 |
Technical Indicators
Market Signals| Indicator | CWST | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 45.45 |
| Support Level | $89.49 | $81.16 |
| Resistance Level | $97.58 | $91.36 |
| Average True Range (ATR) | 3.46 | 3.97 |
| MACD | 0.47 | 1.46 |
| Stochastic Oscillator | 70.95 | 80.52 |
Price Performance
Historical ComparisonAbout CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.